|Bank Leumi||Israel, Tel Aviv, Tel Aviv District|
|Ddguanhuai.com||Beijing, Beijing, China|
|Education Sales Management||Colorado, Littleton, United States|
|Emergent Medical Partners||California, Portola Valley, United States|
|Frontier||Finland, Helsinki, Southern Finland|
|GE Capital Real Estate||-|
|GVC Capital||Colorado, Greenwood Village, United States|
|Jochu Technology||Hsinchu, Taiwan, Taiwan Province|
|L Catterton Europe||France, Ile-de-France, Paris|
|Purple Cow||Brentwood, California, United States|
|RGM Capital||Florida, Naples, United States|
|Scudder Kemper Investments||-|
|Visual Interactive Investments, LLC||-|
|Y Ventures||California, Monrovia, United States|
|YMC||Japan, Kyoto, Kyoto Prefecture|
|$30M||08 Feb 2022||San Francisco, California, United States|
|$60M||14 Dec 2021||New York, New York, United States|
|$24M||09 Dec 2021||Austin, Texas, United States|
|$20M||09 Nov 2021||San Francisco, California, United States|
|$30M||05 Oct 2021||Massachusetts, United States|
|$14M||22 Jun 2021||Nashville, Tennessee, United States|
|$63M||03 Jun 2021||New York, New York, United States|
|$4M||01 May 2021||San Francisco, California, United States|
|$17M||07 Feb 2020||France, Bourgogne-Franche-Comté, France|
– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.
– Workera.ai, a precision upskilling platform, has closed a $16m Series A round.
– The round was led by NEA alongside existing investors Owl Ventures and AI Fund, as well as AI luminaries Richard Socher of AIX Ventures, Pieter Abbeel, Lake Dai and Mehran Sahami.
– This new infusion of capital will be used to accelerate product development and fuel the company’s go-to-market strategy.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.